{"type":"video","version":"1.0","html":"<iframe src=\"https://www.loom.com/embed/91bf703330484310af4af853092f8586\" frameborder=\"0\" width=\"2014\" height=\"1510\" webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>","height":1510,"width":2014,"provider_name":"Loom","provider_url":"https://www.loom.com","thumbnail_height":1510,"thumbnail_width":2014,"thumbnail_url":"https://cdn.loom.com/sessions/thumbnails/91bf703330484310af4af853092f8586-c5698d84378abd96.gif","duration":180.963,"title":"Turning CRISPR Screens into Drug Targets","description":"This Loom presents a pipeline to nominate potential drug targets from a genome-wide CRISPR screen in human CD4 T-cells. The analysis uses cloud science sub-agents to identify usable dataset columns, then compares two axes of hypotheses: activation (stimulation versus resting) and Th1 versus Th2 polarization, prioritizing rankings using log4chang, z-scores, and p-values. The pipeline is validated because it retrieves known targets such as TNFs FR, SR, and SF9, while also producing novel candidates. One highlighted novel target is TATDN2, which the system ranks and links to drugability potential for downstream therapeutic development, culminating in a final report and ranked gene list in Th1-skewing and Th2-skewing directions."}